How do you manage surveillance imaging for patients with metastatic castration-naive prostate cancer with an initial low PSA?  

Low PSA progression is common at the time of radiographic progression in the mHSPC setting, particularly among men treated with potent AR inhibitors. As we recently presented in the ARCHES phase 3 study, while enzalutamide significantly improves rPFS and OS and reduces progression events, among thos...

I fully agree with Dr. @Armstrong's comment that PSA alone is not a reliable indicator of progression in mHSPC. As was seen in the ARCHES trial, patients on CHAARTED trial also showed similar progression patterns. A follow-up analysis of CHAARTED patients (Bryce et al., PMID 32807727) showed  &...